Stocks
Faeth Therapeutics, Inc.FTH
NASDAQHealthcareBiotechnology$20.10
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing metabolism-based therapies for cancer and other diseases. Its pipeline targets nutrient pathways to inhibit tumor growth, with lead programs in early-phase trials. Investors track the company for its novel approach to oncology and potential partnerships with larger drugmakers.
52W Range: $7.45-$42.14
Congressional Interest in Faeth Therapeutics, Inc. (FTH)
No congressional trades have been disclosed for Faeth Therapeutics, Inc. (FTH) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading FTH?
No congressional trades found for this stock.